These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 325130)

  • 1. Characterization of cytolytic effector cells in peripheral blood of healthy individuals and cancer patients. II. Cytotoxicity to allogeneic or autochthonous tumor cells in tissue culture.
    Pape GR; Troye M; Perlmann P
    J Immunol; 1977 Jun; 118(6):1925-30. PubMed ID: 325130
    [No Abstract]   [Full Text] [Related]  

  • 2. Transitional cell carcinoma: lymphocyte-mediated cytotoxicity.
    Troye M; Pape GR
    Natl Cancer Inst Monogr; 1978 Dec; (49):85-7. PubMed ID: 311895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cytolytic effector cells in peripheral blood of healthy individuals and cancer patients. I. Surface markers and K cell activity after separation of B cells and lymphocytes and Fc-receptors by column fractionation.
    Pape GR; Troye M; Perlmann P
    J Immunol; 1977 Jun; 118(6):1919-24. PubMed ID: 325129
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of Fab fragments of anti-human immunoglobulin as analytic tools for establishing the involvement of immunoglobulin in the spontaneous cytotoxicity to cultured tumor cells by lymphocytes from patients with bladder carcinoma and from healthy donors.
    Troye M; Perlmann P; Pape GR; Spiegelberg HL; Näslund I; Gidlöf A
    J Immunol; 1977 Sep; 119(3):1061-7. PubMed ID: 302271
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-associated and spontaneous lymphocyte-mediated cytotoxicity against cell lines derived from human urothelium.
    Vilien M
    Dan Med Bull; 1985 Aug; 32(4):199-218. PubMed ID: 3899526
    [No Abstract]   [Full Text] [Related]  

  • 6. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
    Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
    Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
    Spina CA; Dorey F; Vescera C; Brosman S; Fahey JL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4324-30. PubMed ID: 6458353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-mediated cytotoxicity against human bladder cancer.
    Bloom ET; Ossorio RC; Brosman SA
    Int J Cancer; 1974 Sep; 14(3):326-34. PubMed ID: 4477556
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic evaluation of human bladder cancer: in vitro studies.
    Elhilali MM; Nayak SK
    Cancer; 1975 Feb; 35(2):419-31. PubMed ID: 1111918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of primary tumor bed lymphocytic infiltration and peripheral lymphocyte cytotoxicity in patients with transitional cell carcinoma.
    Jones LW; O'Toole C
    Natl Cancer Inst Monogr; 1978 Dec; (49):183-5. PubMed ID: 748770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoid cells mediating tumor-specific cytotoxicity to carcinoma of the urinary bladder. Separation of the effector population using a surface marker.
    O'Toole C; Stejskal V; Perlmann P; Karlsson M
    J Exp Med; 1974 Mar; 139(3):457-66. PubMed ID: 4591169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24.
    Catalona WJ; Oldham RK; Djeu JY; Herberman RB; Cannon GB
    Surg Forum; 1975; 26():122-4. PubMed ID: 56048
    [No Abstract]   [Full Text] [Related]  

  • 15. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder carcinoma.
    Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
    Invest Urol; 1979 Mar; 16(5):342-5. PubMed ID: 429128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro production of human antibodies against bladder cancer: characterization and diagnostic implications.
    Pizza G; De Vinci C
    J Exp Pathol; 1987; 3(4):335-46. PubMed ID: 2457663
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular cytotoxicity in transitional cell carcinoma of the human urinary bladder - a summary.
    Perlmann P; Troye M; Pape G; Blomgren H; Johansson B
    Urol Res; 1978; 6(4):207-9. PubMed ID: 741533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 51chromium isotope release assay for detecting cytotoxicity to human bladder carcinoma.
    O'Toole C
    Int J Cancer; 1977 Mar; 19(3):324-31. PubMed ID: 844912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cellular immune response of bladder tumor patients: effects of aging on cytotoxic activity against T24].
    Kato M
    Hinyokika Kiyo; 1988 Aug; 34(8):1363-9. PubMed ID: 3195404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.